Title : Radiation Pneumonitis Following Definitive Therapy with Radiation, Chemotherapy, and Immunotherapy
Non small cell lung cancer (NSCLC) remains one of the most common and lethal malignancies across the world, often affecting smokers who have other comorbid conditions which can limit the ability to receive adequate treatment. The current standard of care for stage IIIB NSCLC remains definitive chemotherapy and radiation, now with the addition of immunotherapy based on the groundbreaking results of the PACIFIC trial. Immunotherapy alone can cause pneumonitis, and as such there is concern for potential increase in lung damage with its use after radiation. My talk will focus on the risks of radiation pneumonitis following conventional chemotherapy and radiation with a review of historical data. The PACIFIC trial will be reviewed, highlighting inclusion criteria as it related to radiation dose, as well as rates of pneumonitis in follow up. The treatment, management, and timing of radiation pneumonitis will also be reviewed and highlighted.